miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis

PLoS One. 2018 Jun 14;13(6):e0198932. doi: 10.1371/journal.pone.0198932. eCollection 2018.

Abstract

Background: Atherosclerosis involves activation of the IRAK1/TRAF6/NF-κB inflammatory cascade, which is negatively regulated by miR146a. Previous studies showed that the TT genotype of rs2431697, located near the miR-146a gene, drives lower miR-146a transcription and predicts adverse cardiovascular events in anticoagulated atrial fibrillation patients. Moreover, systemic miR-146a administration protects mice from atherosclerosis. Here we evaluated the ability of miR-146a expression in the hematopoietic component to regulate atherosclerosis in low-density lipoprotein receptor-null mice (Ldlr-/-).

Methods and results: Lethally-irradiated Ldlr-/- mice transplanted with bone marrow from wild-type or miR-146a-null mice were fed an atherogenic diet for 8 and 20 weeks. Irak1, Traf6 and MIR146A expression were quantified in thoracic aorta by qRT-PCR and Western blot. Aortic plaque size and composition were characterized by Oil-Red staining and immunohistochemistry and leukocyte recruitment by intravital microscopy. Blood cell counts were similar in fat-fed Ldlr-/-mice with or without hematopoietic miR-146a expression. However, plasma cholesterol decreased in fat-fed Ldlr-/-mice transplanted with bone marrow deficient for miR-146a. Finally, aortic atherosclerosis burden and recruitment of leukocytes into the vessel wall were undistinguishable between the two groups, despite higher levels of Irak1 and Traf6 mRNA and protein in the aorta of fat-fed mice lacking hematopoietic miR-146a expression.

Conclusions: miR-146a deficiency exclusively in hematopoietic cells modulates cholesterol levels in plasma and the expression of its targets in the artery wall of fat-fed Ldlr-/- mice, but does not accelerate atherosclerosis. Atheroprotection upon systemic miR-146a administration may therefore be caused by specific effects on vascular cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atherosclerosis / genetics*
  • Atherosclerosis / immunology*
  • Cell Adhesion / genetics
  • Disease Progression
  • Gene Expression Regulation
  • Hematopoiesis
  • Humans
  • Leukocytes / cytology
  • Leukocytes / immunology
  • Male
  • Mice
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*

Substances

  • MIRN146 microRNA, human
  • MicroRNAs
  • Mirn146 microRNA, mouse

Grants and funding

This study was supported by research grants from the Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER) [PI14/00253, Red RIC (RD12/0042/0050 and RD12/0042/0028), CIBERCV CB16/11/00405] and 19873/GERM/15 (Fundación Séneca). A.D.M. has a predoctoral contract from the Spanish Ministerio de Economía, Industria y Competitividad (MEIC) (BES-2014-06779) and A.B.A. has a research fellowship from Sociedad Española de Trombosis y Hemostasia (SETH). The CNIC is supported by the Ministerio de Economía, Industria y Competitividad (MEIC) and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.